BioLife Solutions reported a 21% increase in revenue to $40.7 million for Q3 2022, with a strong performance from the cell processing platform. The company achieved positive adjusted EBITDA of $1.4 million, but adjusted the top of the 2022 revenue guidance range due to expected shipment delays related to supply-chain challenges impacting the cryogenic freezer product line.
Total revenue increased by 21% to $40.7 million compared to Q3 2021.
Cell Processing platform revenue increased by 57% over the same period in 2021.
Adjusted EBITDA was $1.4 million for the third quarter.
Tightened 2022 revenue guidance range reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40%.
Total revenue for 2022 is now expected to range from $160 million to $164 million, reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40%.